News

Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism

LONDON, Ontario and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading…

11 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here…

11 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here…

11 months ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the…

11 months ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the…

11 months ago

Vor Bio to Participate in the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

11 months ago

Vor Bio to Participate in the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

11 months ago

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…

11 months ago

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the…

11 months ago

Spectral Medical Provides January Tigris Trial Update

Strong enrollment activity to start 2025146 patients enrolled TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or…

11 months ago